Your Health, We Care

Home > Photo Wall > Honor and qualification

Production approval for Tibsovo

Release date: 2024-07-10 14:28:36     Recommended: 102

07L0988_23 艾伏尼布 批文_00.jpg

Ivosidenib (Tibsovo) is a potent oral IDH1 inhibitor primarily used to treat newly diagnosed adult patients aged ≥ 75 years or unable to use intensified induction chemotherapy due to comorbidities. Adult patients with recurrent or refractory AML. Used for adult patients with locally advanced or metastatic cholangiocarcinoma who have previously received treatment and carry IDH1 mutations detected by FDA approved testing methods. (This indication has not yet been approved in the Chinese market)

Company News

Research News

Drug news